Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical evaluation of therapies such as etanercept, infliximab, ustekinumab, and secukinumab. Dr. Gottlieb will work to help guide the clinical development of bermekimab, the company’s candidate antibody therapy for skin diseases.

Dr. Gottlieb is currently Professor of Dermatology at New York Medical College and former Chair of Dermatology and Dermatologist-in-Chief at the Tufts Medical Center and Tufts University School of Medicine. Dr. Gottlieb was elected to the Board of Directors of the American Academy of Dermatology from 2011-2015 and is the Founder and President of the Board of the International Dermatology Outcome Measures group and co-Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis. Dr. Gottlieb has authored 400 publications and presented her research at more than 200 conferences across the globe. She is triple-boarded in dermatology, rheumatology and internal medicine, one of only a handful of doctors in the U.S. certified in all three specialties. She obtained her MD from Cornell Medical School and her PhD in immunology from the Rockefeller University.

“I am delighted to join XBiotech’s Scientific Advisory Board and serve as the lead investigator for the ongoing Phase 2 study of bermekimab for hidradenitis suppurativa. This disease is painful, scarring and humiliating. We need new therapies which are effective in more patients and to a higher degree. I am looking forward to working with XBiotech to further develop bermekimab in dermatology,” Dr. Gottlieb says.

John Simard adds, “I am so delighted to have Alice join our team. We value her extraordinary insights and experience in developing biological treatments for skin diseases. I look forward to working together with her to advance our new therapy in dermatology.”

Dr. Gottlieb currently serves as the Study Chair for the Company’s on-going phase 2, open label clinical study to evaluate subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). The study includes a 13 week treatment regimen, treating both patients having failed anti-TNF therapy and those with no prior anti-TNF treatment history. Results from a randomized, placebo controlled, Phase 2 study were published earlier this year in the Journal of Investigative Dermatology, reporting a significant improvement in HS patients treated with bermekimab after 12 weeks of therapy (Response rate of 60% vs 10%, respectively (p=0.035)). The 20 patient study evaluated the safety and efficacy of bermekimab intravenous infusion in patients with HS not eligible for anti-TNF therapy. In the new study headed by Dr. Gottlieb, a subcutaneous formulation, that can be conveniently administered using the Company’s new pre-filled syringes, is being evaluated.